04:11 PM EDT, 09/09/2025 (MT Newswires) -- Serina Therapeutics ( SER ) has entered into a $20 million structured financing agreement as it looks to further registration of its drug candidate for the treatment of Parkinson's disease, it said Tuesday.

The biotech company reported the financing also includes issuance of warrants, which could lead to additional proceeds of up to $20 million, if fully exercised.

Under the deal, the company may access the total amount via issuance of an unsecured convertible note in five tranches, giving it the flexibility to deploy capital in line with trial progress. It will also allow Serina to draw additional non-diluted and strategic funding, it added.

The company plans to submit application to the US Food and Drug Administration in fourth quarter to initiate clinical trials of the experimental drug, SER 252. It expects to commence dosing patients in Australia during the same period as part of its global registration program.

Price: 5.04, Change: -0.14, Percent Change: -2.66